Dalbavancin - CAS 171500-79-1
Catalog number:
B0084-169772
Category:
Inhibitor
Not Intended for Therapeutic Use. For research use only.
Molecular Formula:
C88H100Cl2N10O28
Molecular Weight:
1816.69
COA:
Inquire
Targets:
Antibacterial
Description:
Dalbavancin is a semi-synthetic glycopeptide by introducing a positively charged lipophilic moiety in a previously unexplored region of the natural glycopeptide. This modification provides a longer in vivo half life, and improved in vitro activity against a variety of Gram positive and multi-drug resistant isolates such as MRSA and MRSE.
Ordering Information
Catalog Number Size Price Stock Quantity
B0084-169772 50 mg $198 In stock
Bulk Inquiry
Publictions citing BOC Sciences Products
  • >> More
Purity:
>98%
Appearance:
Off-white solid powder
Synonyms:
Ristomycin A aglycone, 5,​31-​dichloro-​38-​de(methoxycarbonyl)​-​7-​demethyl-​19-​deoxy-​56-​O-​[2-​deoxy-​2-​[(10-​methyl-​1-​oxoundecyl)​amino]​-​β-​D-​glucopyranuronosyl]​-​38-​[[[3-​(dimethylamino)​propyl]​amino]​carbonyl]​-​42-​O-​α-​D-​mannopyranosyl-​N15-​methyl-; A-A 1; BI397; BI-397; BI 397; VER 001; VER-001; VER001; MDL63397; MDL-63397; MDL 63397; Dalbavancin Dalbavancin B0; trade name: Dalvance in the US and Xydalba in Europe
MSDS:
Inquire
InChIKey:
PEXPCJWLNBNBNT-AXKGEONOSA-N
InChI:
1S/C88H100Cl2N10O28.ClH/c1-38(2)13-10-8-6-7-9-11-14-61(106)94-70-73(109)75(111)78(86(120)121)128-87(70)127-77-58-31-43-32-59(77)124-55-24-19-42(29-50(55)89)71(107)69-85(119)98-67(80(114)92-25-12-26-100(4)5)48-33-44(102)34-57(125-88-76(112)74(110)72(108)60(37-101)126-88)62(48)47-28-40(17-22-52(47)103)65(82(116)99-69)95-83(117)66(43)96-84(118)68-49-35-46(36-54(105)63(49)90)123-56-30-41(18-23-53(56)104)64(91-3)81(115)93-51(79(113)97-68)27-39-15-20-45(122-58)21-16-39;/h15-24,28-36,38,51,60,64-76,78,87-88,91,101-105,107-112H,6-14,25-27,37H2,1-5H3,(H,92,114)(H,93,115)(H,94,106)(H,95,117)(H,96,118)(H,97,113)(H,98,119)(H,99,116)(H,120,121);1H/t51-,60-,64-,65-,66-,67+,68+,69+,70-,71-,72-,73-,74+,75+,76+,78+,87-,88+;/m1./s1
Canonical SMILES:
CC(CCCCCCCCC(N[C@@H]1[C@@H](O)[C@H](O)[C@@H](C(O)=O)O[C@H]1OC2=C3C=C4C=C2OC5=C(Cl)C=C([C@@H](O)[C@H]6C(N[C@H](C(NCCCN(C)C)=O)C7=CC(O)=CC(O[C@@H]8[C@@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O8)=C7C9=C(O)C=CC([C@@H](NC([C@@H]4NC([C@@H]%10C%11=CC(OC%12=C(O)C=CC([C@@H](NC)C(N[C@@H](C(N%10)=O)CC%13=CC=C(C=C%13)O3)=O)=C%12)=CC(O)=C%11Cl)=O)=O)C(N6)=O)=C9)=O)C=C5)=O)C.Cl
1.Safety of Dalbavancin in the Treatment of Skin and Skin Structure Infections: A Pooled Analysis of Randomized, Comparative Studies.
Dunne MW1, Talbot GH2, Boucher HW3, Wilcox M4,5, Puttagunta S6. Drug Saf. 2016 Feb;39(2):147-57. doi: 10.1007/s40264-015-0374-9.
INTRODUCTION: Dalbavancin is a new lipoglycopeptide that is active against Gram-positive pathogens, including methicillin-resistant Staphylococcus aureus. It has a half-life of 14.4 days, permitting intravenous treatment of acute bacterial skin and skin structure infections without the need for daily dosing.
2.Dalbavancin Activity when Tested against Streptococcus pneumoniae Isolated in Medical Centers on Six Continents (2011-2014).
Jones RN1, Schuchert JE2, Mendes RE2. Antimicrob Agents Chemother. 2016 Mar 21. pii: AAC.00116-16. [Epub ahead of print]
Dalbavancin, a novel lipoglycopeptide, was approved in 2014 by regulatory agencies in the United States (USA) and Europe for the treatment of skin and skin structure infections. The activity of dalbavancin was also widely assessed against Streptococcus pneumoniae clinical isolates collected from patients on six continents monitored during two time intervals (2011-2013 and 2014). A total of 18,186 pneumococci were obtained from 49 nations and submitted to a monitoring laboratory as part of the SENTRY Antimicrobial Surveillance Program for reference susceptibility testing. Dalbavancin potency against S. pneumoniae was consistent across the monitored years with a MIC50/90 of 0.015/0.03 μg/ml and all isolates were inhibited at ≤ 0.12 μg/ml. The activity for dalbavancin was not adversely influenced by non-susceptibility to β-lactams (ceftriaxone or penicillin), macrolides, clindamycin, fluoroquinolones, tetracyclines or multidrug-resistance (MDR).
3.Comparative In vitro Activity of Oritavancin, Dalbavancin and Vancomycin against Methicillin-Resistant Staphylococcus aureus Isolates in a Non-Dividing State.
Belley A1, Lalonde Seguin D1, Arhin F1, Moeck G1. Antimicrob Agents Chemother. 2016 Apr 11. pii: AAC.00169-16. [Epub ahead of print]
Antibacterial agents that kill non-dividing bacteria may be of utility in treating persistent infections. Oritavancin and dalbavancin are bactericidal lipoglycopeptides approved for acute bacterial skin and skin structure infections in adults caused by susceptible gram-positive pathogens. Using time-kill methodology, we demonstrate that oritavancin exerts bactericidal activity against methicillin-resistantStaphylococcus aureus(MRSA) isolates maintained in a non-dividing state in vitro whereas dalbavancin and the glycopeptide vancomycin do not.
4.New developments in the treatment of acute bacterial skin and skin structure infections: considerations for the effective use of dalbavancin.
Juul JJ1, Mullins CF1, Peppard WJ1, Huang AM1. Ther Clin Risk Manag. 2016 Feb 16;12:225-32. doi: 10.2147/TCRM.S71855. eCollection 2016.
Dalbavancin, an intravenous glycopeptide, was approved by the US Food and Drug Administration in May 2014 for use in adult patients with acute bacterial skin and skin structure infections. The recommended dosing regimen for effective use of dalbavancin is 1,000 mg followed by a 500 mg dose after 1 week. Two multinational, identically designed, non-inferiority trials, DISCOVER 1 and 2, demonstrated similar early clinical success with dalbavancin compared to vancomycin with an option to switch to oral linezolid. In a recently published non-inferiority trial, a single-dose regimen of dalbavancin was compared to the traditional two-dose administration and was found to have a non-inferior clinical response. In the aforementioned trials, dalbavancin was well tolerated, with patients experiencing transient adverse events of mild to moderate severity. The prolonged half-life, excellent skin and soft tissue penetration, bactericidal activity against Gram-positive bacteria including methicillin-resistant Staphylococcus aureus, and convenient dosing make dalbavancin a reasonable option for the treatment of acute bacterial skin and skin structure infections in adult patients who have tried and failed other therapies.
Molecular Weight Calculator Molarity Calculator Solution Dilution Calculator

Related Antibacterial Products


CAS 6054-98-4 Olsalazine Sodium

Olsalazine Sodium
(CAS: 6054-98-4)

Olsalazine Sodium is an anti-inflammatory prodrug, which consists of two 5-ASA moieties linked by an azo bond. It is used in the treatment of inflammatory bowel...

CAS 22862-76-6 Anisomycin

Anisomycin
(CAS: 22862-76-6)

Anisomycin is an antibiotic, which inhibits protein synthesis, and also act as a JNK activator.

CAS 97519-39-6 Ceftibuten

Ceftibuten
(CAS: 97519-39-6)

Ceftibuten is a third-generation cephalosporin antibiotic. It displayed high activity against Haemophilus influenzae and Branhamella catarrhalis. It is an orall...

CAS 18472-51-0 Chlorhexidine digluconate

Chlorhexidine digluconate
(CAS: 18472-51-0)

Chlorhexidine has been used to study how essential oils improve skin antisepsis when combined with chlorhexidine digluconate and is used for skin permeation stu...

CAS 105956-97-6 Clinafloxacin

Clinafloxacin
(CAS: 105956-97-6)

Clinafloxacin is a broad-spectrum antibiotic of the quinolone carboxylic acid category currently in development for intravenous and oral therapy of serious infe...

CAS 65710-07-8 Apramycin Sulfate

Apramycin Sulfate
(CAS: 65710-07-8)

Apramycin is an aminoglycoside antibiotic. It acts by blocking translocation and binding also to the eukaryotic decoding site despite differences in key residue...

CAS 35523-45-6 Fludalanine

Fludalanine
(CAS: 35523-45-6)

Fludalanine, an analogue of D-alanine that irreversibly inactivates the racemase, inhibits the synthetase.

CAS 93106-60-6 Enrofloxacin

Enrofloxacin
(CAS: 93106-60-6)

Enrofloxacin is a fluoroquinolone antibiotic acting by inhibiting bacterial DNA gyrase (a type-II topoisomerase), thereby preventing DNA supercoiling and DNA sy...

CAS 91832-40-5 Cefdinir

Cefdinir
(CAS: 91832-40-5)

Cefdinir is a semi-synthetic, broad-spectrum antibiotic, used for soft tissue infections and respiratory tract infections

CAS 58-71-9 Cephalothin sodium

Cephalothin sodium
(CAS: 58-71-9)

Cephalothin sodium is a semisynthetic first generation cephalosporin having a broad spectrum of antibiotic activity that is administered parenterally used to pr...

CAS 2058-46-0 Oxytetracycline hydrochloride

Oxytetracycline hydrochloride
(CAS: 2058-46-0)

Oxytetracycline hydrochloride, a tetracycline derivative isolated from the elaboration products of the actinomycete, Streptomyces rimosus, is an antibacterial c...

CAS 1070-11-7 Ethambutol HCl

Ethambutol HCl
(CAS: 1070-11-7)

Ethambutol is a bacteriostatic antimycobacterial agent, which obstructs the formation of cell wall by inhibiting arabinosyl transferases.

CAS 1476-53-5 Novobiocin Sodium

Novobiocin Sodium
(CAS: 1476-53-5)

Novobiocin Sodium is a very potent bacterial DNA gyrase and human organic anion transporters with Ki of 14.87 ± 0.40 μM for hOAT1, 4.77 ± 1.12 μM for hOAT3 and ...

CAS 9001-63-2 Lysozyme

Lysozyme
(CAS: 9001-63-2)

Lysozyme is an antimicrobial enzyme produced by animals, damaging bacterial cell walls via hydrolysis between residues in peptidoglycan walls.

CAS 115551-26-3 Marbofloxacin hydrochloride

Marbofloxacin hydrochloride
(CAS: 115551-26-3)

Marbofloxacin hydrochloride is a potent antibiotic by inhibiting DNA-gyrase.

CAS 140-64-7 Pentamidine isethionate

Pentamidine isethionate
(CAS: 140-64-7)

The diisethionate salt form of Pentamidine, an amidine derivative, has been found to have antiprotozoal and antifungal effect and could be commonly used against...

CAS 52152-93-9 Cefsulodine sodium

Cefsulodine sodium
(CAS: 52152-93-9)

Cefsulodin is a third generation cephalosporin (C258750) antibiotic designed specifically for Pseudomonas Aeruginosa.

LY 186826
(CAS: 126165-79-5)

LY 186826 is an antibacterial agent with bicyclic pyrazolidinones containing a novel aza-γ-lactam ring structure. The properties of this compound appear to be r...

CAS 161715-24-8 Tebipenem Pivoxil

Tebipenem Pivoxil
(CAS: 161715-24-8)

Tebipenem Pivoxil has high intestinal apical membrane permeability due to plural intestinal transport routes, including the uptake transporters such as OATP1A2 ...

CAS 80621-81-4 Rifaximin

Rifaximin
(CAS: 80621-81-4)

Rifaximin, an orally administered, semi-synthetic, nonsystemic antibiotic derived from rifamycin SV with antibacterial activity.

Chemical Structure

CAS 171500-79-1 Dalbavancin

Quick Inquiry

Verification code

Featured Items